25,975 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Acquired by Koa Wealth Management LLC

Koa Wealth Management LLC acquired a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 25,975 shares of the company’s stock, valued at approximately $83,000.

Other large investors have also recently modified their holdings of the company. FMR LLC boosted its holdings in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Perspective Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after buying an additional 355,685 shares in the last quarter. State Street Corp grew its position in Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after acquiring an additional 1,192,812 shares during the last quarter. Nicholson Wealth Management Group LLC purchased a new position in shares of Perspective Therapeutics during the third quarter worth approximately $21,390,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Perspective Therapeutics by 12.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,164,204 shares of the company’s stock worth $15,546,000 after acquiring an additional 129,654 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Price Performance

NYSE:CATX opened at $3.81 on Friday. Perspective Therapeutics, Inc. has a one year low of $2.70 and a one year high of $19.05. The company’s 50-day simple moving average is $3.51 and its 200 day simple moving average is $9.57.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The business had revenue of $0.37 million during the quarter. On average, equities research analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CATX. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Friday, January 24th. Royal Bank of Canada reissued an “outperform” rating and issued a $16.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Oppenheimer cut their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. UBS Group started coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. Finally, Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $24.00 to $5.00 in a report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Perspective Therapeutics has an average rating of “Moderate Buy” and an average price target of $15.14.

Insiders Place Their Bets

In other Perspective Therapeutics news, CFO Jonathan Robert Hunt purchased 12,829 shares of Perspective Therapeutics stock in a transaction dated Monday, November 25th. The stock was purchased at an average price of $3.82 per share, with a total value of $49,006.78. Following the transaction, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at $186,416. This trade represents a 35.66 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Johan M. Spoor bought 8,000 shares of Perspective Therapeutics stock in a transaction on Wednesday, December 4th. The shares were acquired at an average cost of $3.77 per share, with a total value of $30,160.00. Following the completion of the acquisition, the chief executive officer now owns 36,257 shares of the company’s stock, valued at $136,688.89. The trade was a 28.31 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 67,570 shares of company stock valued at $256,789. Insiders own 3.52% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.